Get the app
US › Healthcare

Acumen Pharmaceuticals Inc (ABOS)

US · Healthcare · Biotechnology

$1.69+1.20%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-32.7M
EPS
$-0.45
EPS estimate
$-0.39

EPS came in at -0.45 against a street estimate of -0.39 — a miss of 15.4%.

Key statistics

Market cap
$131.3M
Forward P/E
0.0
P/B
2.91
Book value
$0.79
EPS (TTM)
$-1.64
52-week high
$3.60
52-week low
$1.50
50-day MA
$2.60
200-day MA
$2.51
Beta
0.33

Analyst view

Analysts rate Acumen Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $7.60.

Shareholding

Insiders
6.79%
Institutions
66.59%

Largest institutional holders

FundStake
RA Capital Management, LLC29.03%
Sands Capital Ventures, LLC5.14%
BlackRock Inc3.44%
Alyeska Investment Group, L.P.3.39%
Franklin Templeton Inc3.19%
ADAR1 Capital Management LLC2.92%
Vanguard Capital Management, LLC2.31%
Knollwood Investment Advisory LLC2.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Acumen Pharmaceuticals Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.